ライフサイエンスコーパス: ELISPOT

1 ELISPOT analysis of T cell responses to 122 individual p

2 ELISPOT analysis revealed that CFA promoted the differen

3 ELISPOT analysis uncovered an Ag-specific FasL/IL-22-sec

4 ELISPOT and cytotoxicity assays were used to evaluate tu

5 ELISPOT assays may be used to identify HIV-infected pati

6 ELISPOT detection of IFN-gamma-producing T cells showed

7 ELISPOT response was independently associated with SVR b

8 ELISPOT responses were examined relative to human leukoc

9 virin; 43% of patients who had more than 168 ELISPOTs/10(6) peripheral blood mononuclear cells (above

10 We used an IL-17 ELISPOT assay to track the neuroantigen-specific IL-17-p

11 lear cells (P = .004; T4 vs T5) for the IL-2 ELISPOT assay and 103 and 380 SFCs/10(6) PBMCs (P = .003

12 aluated empirically using IFN-gamma and IL-2 ELISPOT using immunodominant Ags (Acr-1, CFP-10, ESAT-6)

13 responses as detected by IFN-gamma and IL-2 ELISPOT, while also improving OVA-specific humoral B cel

14 Of the remaining 24 ELISPOT (+) patients with no induction therapy, acute re

15 Of the 32 ELISPOT (+) patients, eight received induction therapy a

16 Using IFN-gamma and IL-5 ELISPOT assays and PBL from patients with NY-ESO-1-expre

17 otein production, as determined by TNF-alpha ELISPOT assays.

18 ith in vitro anti-HLA T cell responses in an ELISPOT assay (p = 0.008 versus antibody-positive patien

19 lymphocytes in response to alloantigen in an ELISPOT assay and higher IFN-gamma levels in placental h

20 H1N1-stimulated IgG Ab-secreting cells in an ELISPOT assay.

21 h less HD exposure had a low incidence of an ELISPOT (+) test, similar to nonblack recipients.

22 s determined pre and post-treatment using an ELISPOT assay.

23 ned a significant positive correlate with an ELISPOT (+) result (odds ratio per year of HD 1.3; P = 0

24 on, enzyme-linked immunoadsorbent assay, and ELISPOT assays.

25 at the cellular level by flow cytometry and ELISPOT assay and mRNA level for retinoic acid-related o

26 (C57BL/6) mice and high-throughput ELISA and ELISPOT analyses of synthetic peptides.

27 nstream experiments using RT-PCR, ELISA, and ELISPOT confirmed the increased expression and secretion

28 Using the Lysispot and ELISPOT assays, we measured the frequencies of cytotoxic

29 n of B cell populations to generate mAbs and ELISPOT assays have been used to determine B cell and Ab

30 ry CXCL9 monitoring, epitope mismatches, and ELISPOT assays are potentially informative, complete CNI

31 diction of HLA class II-binding peptides and ELISPOT assays with PBMC from allergic donors, resulting

32 vitro assays (mixed lymphocyte reaction and ELISPOT) revealed donor-specific tolerance before and af

33 ost likely due to increased Ab catabolism as ELISPOT assays demonstrated that infected animals do not

34 (IFN-gamma) enzyme-linked immunospot assay (ELISPOT) and antibody assay.

35 measured by enzyme-linked immunospot assay (ELISPOT) at multiple time points assessed the magnitude

36 ytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-cell subsets in 59 subjects, inclu

37 a-interferon enzyme-linked immunospot assay (ELISPOT).

38 Enzyme-linked immunosorbent spot assay (ELISPOT) analyses indicated that enhanced inflammation i

39 amma enzyme-linked immunosorbent spot assay (ELISPOT) assay were assessed in the Evaluation of Sub-Cl

40 mma) enzyme-linked immunosorbent spot assay (ELISPOT) data.

41 and enzyme-linked immunosorbent spot assay (ELISPOT) responses to MSP142 3D7 were associated with de

42 [IFN] gamma enzyme-linked immunospot assay [ELISPOT]) immune response to smallpox vaccine in 1076 im

43 ns vivo delayed-type hypersensitivity assay, ELISPOT and antigen-specific HLA tetramer analysis addre

44 vA-specific enzyme-linked immunospot assays (ELISPOT) responses.

45 aining assays, as well as cytokine-augmented ELISPOT and peptide-stimulated tetramer assays, failed t

46 d PBMC were used for perforin and granzyme B ELISPOT and flow cytometry.

47 N may explain the low background of baseline ELISPOT responses in LNs as compared with PBMCs, and the

48 cells 1 (MART-1), also known as Melan-A, by ELISPOT assay following local rV-B7.1 vaccination.

49 and 41 age-matched controls were assayed by ELISPOT using a library of 23 overlapping dipeptide pool

50 ith diminished T cell priming as assessed by ELISPOT.

51 clear cells from ileum, spleen, and blood by ELISPOT.

52 ncreased numbers of DENV-1-specific cells by ELISPOT and higher avidity against DENV-1 of supernatant

53 he frequency of granzyme B positive cells by ELISPOT assay after mitogen stimulation.

54 rsor state to mature PCs, and demonstrate by ELISPOT that these are Ab-secreting cells (ASCs).

55 T cells with intracellular IL-17 detected by ELISPOT assays.

56 feron (IFN-gamma) responses were detected by ELISPOT in 15/31 volunteers to multiple class I- and/or

57 As determined by ELISPOT assay, the magnitude and frequency of IFN-gamma-

58 TL) by RNA-transfected DCs was determined by ELISPOT assays.

59 ber of cells producing IgE, as determined by ELISPOT.

60 We evaluated, by ELISPOT assay, GrB activity in response to 3 overlapping

61 IL-17-producing T cells were identified by ELISPOT bioassay.

62 frequency far higher than that indicated by ELISPOT assay.

63 case when the total response was measured by ELISPOT analysis with virus-infected cells as stimulator

64 ral load, and immunogenicity (as measured by ELISPOT and proliferation assays) were assessed.

65 mory responses to influenza were measured by ELISPOT assay after polyclonal activation of B cells in

66 ile CD4(+) Th1 and Th2 responses measured by ELISPOT assay were similar in the three mouse strains, T

67 to donor or third-party cells as measured by ELISPOT were determined for a total of 126 kidney recipi

68 T-cell response, measured by ELISPOT, was much higher in mice immunized with gp120(al

69 IFNgamma-producing, donor-reactive PBMCs by ELISPOT has potential utility as an immune monitoring to

70 d levels of vaccine-specific plasmablasts by ELISPOT 1 week after immunization of young and elderly a

71 y grass (TG)-specific cytokine production by ELISPOT after in vitro expansion with TG-peptide pools.

72 ined for anti-Gal and total Ig production by ELISPOT.

73 e-secreting cells (CSCs) were quantitated by ELISPOT in mononuclear cells of local and systemic tissu

74 In this study, we show by ELISPOT analysis that compared with normal hearing age-

75 c IgM Ab-producing cells in these tissues by ELISPOT assay.

76 ripheral blood mononuclear cells) ex vivo by ELISPOT in 77% (258/354) of people receiving vaccine; 21

77 hy controls, using flow cytometry and B cell ELISPOT, respectively.

78 d using surface plasmon resonance and B cell ELISPOTs were used to measure plasmablast and memory B c

79 unctionalities of allergen-specific T cells, ELISPOT assays with sets of overlapping peptides coverin

80 We therefore modified the conventional ELISPOT to develop a Quad-Color FluoroSpot to provide a

81 ination of HCMV-specific T cells by cultured ELISPOT, in pregnant women with primary HCMV infection,

82 t women with primary infection, the cultured ELISPOT assay detected a higher T-cell response to pp65

83 Strikingly, the cultured ELISPOT response to pp65 (but not to IE-1 or IE-2) was s

84 During primary infection, the cultured ELISPOT response was mainly mediated by CD4+ T cells, an

85 type 1 diabetes were quantified by cytokine ELISPOT in HLA-typed patients characterized for Abs to I

86 er novel immunosuppressants we used cytokine ELISPOT and ELISAs to screen extracts from 53 traditiona

87 that used overlapping peptides and cytokine ELISPOTs--for three independent class II molecules.

88 Purified protein derivative ELISPOT responses increased over 4 weeks in the predniso

89 d, and placebo-controlled trial of INH in EC ELISPOT and Mantoux test positive participants.

90 The proportions of EC ELISPOT-positive subjects reduced over time (P < 0.001)

91 , 12 470, 8545, 3470, and 9655 and mean EnvA ELISPOT responses were 397, 178, 736, 196, and 1311 SFC/

92 to obtain splenocytes and kidney samples for ELISPOT, mixed leukocyte reaction, and immunohistochemic

93 us infection, 1 had a VV-specific IFN- gamma ELISPOT response, 4 had LP responses against whole VV, 7

94 infection, 6 of 7 individuals had IFN- gamma ELISPOT responses, all had VV-specific LP responses, and

95 I], 1.4,1.7], P value < .0001) and IFN-gamma ELISPOT (estimated GMFR = 2.0 [95% CI, 1.6,2.6], P value

96 iferation (P = .06), but lower for IFN-gamma ELISPOT (P = .02).

97 mononuclear cells were analyzed by IFN-gamma ELISPOT analysis and induction of both survivin-specific

98 IFN-gamma ELISPOT analysis of CD4 T cells isolated from vaccinated

99 IFN-gamma ELISPOT and (51)Cr-release assays showed that HLA-A2-res

100 quamous cell carcinoma cells using IFN-gamma ELISPOT and [(51)Cr]release assay.

101 1+ SIV-infected rhesus macaques in IFN-gamma ELISPOT and IFN-gamma/TNF-alpha intracellular cytokine s

102 ymphocyte responses, determined by IFN-gamma ELISPOT and proliferation assays, were strong before and

103 osis H37Rv (hkH37Rv) were used for IFN-gamma ELISPOT and RNA extraction.

104 itopes, we validated the method by IFN-gamma ELISPOT assay and found three novel peptides that induce

105 a finding not revealed by standard IFN-gamma ELISPOT assay currently in use in vaccine trials, which

106 , peripheral blood, donor-reactive IFN-gamma ELISPOT assay results correlated with development of DSA

107 ensitive and reproducible cultured IFN-gamma ELISPOT assay, positive responses mainly mediated by CD4

108 Using an IFN-gamma ELISPOT assay, we identified two ALK-derived DRB1-restri

109 PBMCs (P = .003; T4 vs T5) for the IFN-gamma ELISPOT assay.

110 coculture suppression assay and an IFN-gamma ELISPOT assay.

111 d host T cells was measured by the IFN-gamma ELISPOT assay.

112 and long-term infection using the IFN-gamma ELISPOT assay.

113 pport the concept that the GrB and IFN-gamma ELISPOT assays measure immune responses in different imm

114 We used single-cell resolution IFN-gamma ELISPOT assays to measure the frequencies and functional

115 carriers were screened in ex vivo IFN-gamma ELISPOT assays using peptides spanning the two IE, six r

116 ing Vbeta spectratype analysis and IFN-gamma ELISPOT assays, suggesting that new miHA differences had

117 ation against Tyrp1 as assessed by IFN-gamma ELISPOT assays.

118 RS convalescent samples by ex vivo IFN-gamma ELISPOT assays.

119 skin reaction, a clear increase in IFN-gamma ELISPOT counts was seen in the draining LN but not in PB

120 adin peptides were next assayed by IFN-gamma ELISPOT for recognition in peripheral blood cells of CD

121 IFN-gamma ELISPOT geometric mean fold rises (GMFR) after dose 4 in

122 cell responses was assessed using IFN-gamma ELISPOT in 28 children who underwent UCBT to treat hemat

123 IFN-gamma ELISPOT is probably not a useful biomarker of treatment

124 ection of the initial SIV-specific IFN-gamma ELISPOT response in SIVsmE041-infected SM coincided temp

125 The peak ex vivo IFN-gamma ELISPOT response in this group correlated strongly with

126 absent or >10-fold lower than the IFN-gamma ELISPOT response to the same SIV protein.

127 L18R1 haplotypes and variations in IFN-gamma ELISPOT responses (global P < .0001).

128 and analyzed its correlation with IFN-gamma ELISPOT responses and plasma viral load.

129 repeatedly to produce significant IFN-gamma ELISPOT responses in both acute-infection and relapsing

130 rhBZLF1-specific IFN-gamma ELISPOT responses ranging between 56 and 3070 spot-formi

131 re frequent (P < .05) HCV-specific IFN-gamma ELISPOT responses than controls or noninjecting EUs.

132 regimen producing stronger ex vivo IFN-gamma ELISPOT responses than DDM-CS.

133 HSV-specific LP responses, 85% had IFN-gamma ELISPOT responses to at least one HSV-2 peptide pool, an

134 e, there was a striking absence of IFN-gamma ELISPOT responses to recall Ags (purified protein deriva

135 n comparison to peptide responses, IFN-gamma ELISPOT responses to recombinant MSP1(42) were more prev

136 In some cases, IFN-gamma ELISPOT responses were in excess of 500 spot-forming cel

137 tide pool, and 55% had both LP and IFN-gamma ELISPOT responses.

138 cell epitope mapping studies using IFN-gamma ELISPOT was performed on PBMCs from HIV-1-uninfected vac

139 on-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) and VZV antibody concentrations by glycoprotein

140 e-linked immunosorbent spot assay (IFN-gamma ELISPOT) using blood, T cell breadth did not differ sign

141 on-gamma enzyme-linked immunospot (IFN-gamma ELISPOT), blood samples were collected at baseline, post

142 was analyzed by tetramer binding, IFN-gamma ELISPOT, and cytotoxicity assays.

143 spectrometry, cytotoxicity assays, IFN-gamma ELISPOT, and human breast cancer cell lines were used to

144 CD8+ T cell responses, assessed by IFN-gamma ELISPOT, CD107a/b cytotoxic degranulation, and tetramer

145 Gag-specific IFN-gamma ELISPOT, intracellular cytokine staining (ICS) (CD107a,

146 2 overexpression were evaluated by IFN-gamma ELISPOT.

147 their specificity was assessed by IFN-gamma ELISPOT.

148 st-dose 4, measured by gpELISA and IFN-gamma ELISPOT.

149 nd footpad were investigated using IFN-gamma ELISPOT.

150 with mixed lymphocyte reaction and INF-gamma ELISPOT before (D0) and after KT (D9).

151 serotype III at enrollment, interferon gamma ELISPOT positivity was more common in those in whom colo

152 boroPro were measured using interferon gamma ELISPOT.

153 ells ex vivo with validated interferon-gamma ELISPOT and intracellular cytokine staining assays, usin

154 ed protein derivative) with interferon-gamma ELISPOT and intracellular cytokine staining.

155 responses were measured by interferon-gamma ELISPOT and virus neutralization assay up to 12 months a

156 ponse was measured using an interferon-gamma ELISPOT assay.

157 lymerase chain reaction and interferon-gamma ELISPOT assays were used to measure donor-specific react

158 The vaccine elicited interferon-gamma ELISPOT responses in 75% (267) of the 25% random sample

159 The use of interferon-gamma ELISPOT test is a valid tool for immunological monitorin

160 loreactive T-cell immunity (interferon-gamma ELISPOT) at 0, 2, 4, and 12 weeks after vaccination.

161 01), and higher numbers of ex vivo IFN-gamma ELISPOTs (mean, 212 vs 96 spots/million cells; P < .001)

162 IFN-gamma ELISPOTs have been a central methodology to measure T ce

163 in both ex vivo gamma interferon (IFN-gamma) ELISPOT (group mean, 210 spot-forming cells/10(6) cells)

164 ngue virus (DENV) was tested using IFN-gamma-ELISPOT and IFN-gamma-ICS on CD8(+) T cells from DENV-in

165 Using IFN-gamma-ELISPOT and multiparametric FACS analysis, we characteri

166 gthen the concept that used of the IFN-gamma-ELISPOT assay alone may be insufficient to detect critic

167 In this study, we used IFN-gamma-ELISPOT assays and flow cytometry to assess lung and blo

168 ssed by a combination of tetramer, IFN-gamma-ELISPOT, CFSE proliferation, CD107a/b cytotoxic degranul

169 sentation in vitro, vCP205 generated greater ELISPOT responses than Myr- vCP205.

170 g immunological assays (flow cytometry, ICS, ELISPOT).

171 ng procedure (SOP) for alloreactive IFNgamma ELISPOT assays in several research laboratories supporte

172 s on cellular alloimmunity using an IFNgamma ELISPOT assay and on alloantibody reactivity by flow cyt

173 This standardization of IFNgamma ELISPOT assay will facilitate interpretation of data fro

174 Env antigens, and the magnitude of IFNgamma ELISPOT responses (median 521 SFU/10(6) peripheral blood

175 ation assays and interferon gamma (IFNgamma) ELISPOT assays were used to assess peritumoral lymphocyt

176 We found IFNgamma-ELISPOT positive responses to 23 conserved HRV-specific

177 ma interferon (IFN-gamma) enzyme immunospot (ELISPOT) assays.

178 t was supported by enzyme-linked immunospot (ELISPOT) analyses indicating combined INS/IGRP-SPs dimin

179 terleukin-5 (IL-5) enzyme-linked immunospot (ELISPOT) analyses were used to quantify and compare Th1

180 , as determined by enzyme-linked immunospot (ELISPOT) analysis.

181 feron (IFN)- gamma enzyme-linked immunospot (ELISPOT) and CD8(+) and CD4(+) intracellular IFN- gamma

182 g RSV infection by enzyme-linked immunospot (ELISPOT) and intracellular cytokine assays for both lymp

183 rferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and intracellular cytokine staining (ICS) in ZI

184 using HCV peptide enzyme-linked immunospot (ELISPOT) and multiplex in vitro cytokine production assa

185 rferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay (P = 2 x 10(-10)) and functionally throug

186 ith a CMV-specific enzyme-linked immunospot (ELISPOT) assay and for CMV infection from the period bef

187 feron (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay and interleukin (IL)-10 ELISA.

188 y gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining.

189 Interferon-gamma enzyme-linked immunospot (ELISPOT) assay and tetramer analysis showed an increase

190 a gamma interferon enzyme-linked immunospot (ELISPOT) assay for evaluation of CMI responses to rotavi

191 rferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay for HLA class I-restricted, epitope-speci

192 rferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay in 187 Caucasian American (CA) and 187 Af

193 s were detected by enzyme-linked immunospot (ELISPOT) assay in cell suspensions made from the foreski

194 ron (IFN)-gamma by enzyme-linked immunospot (ELISPOT) assay is currently used as a surrogate measurem

195 ex vivo IFN-gamma enzyme-linked immunospot (ELISPOT) assay responses of 19 dually infected individua

196 rferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay responses targeting a median of four SIV

197 feron (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay responses; 21 (50%) of 42 had lymphoproli

198 o, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized pools of overlapping synthe

199 METHODSWe used the enzyme-linked immunospot (ELISPOT) assay to characterize the T cell responses agai

200 rferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay were restricted by four of the five trans

201 l lines, IFN-gamma enzyme-linked immunospot (ELISPOT) assay with peripheral blood mononuclear cells,

202 ) were measured by enzyme-linked immunospot (ELISPOT) assay, and antibody responses were measured by

203 d CD8(+) IFN-gamma enzyme-linked immunospot (ELISPOT) assay.

204 rferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay.

205 ulin G (IgG) in an enzyme-linked immunospot (ELISPOT) assay.

206 ools in a cultured enzyme-linked immunospot (ELISPOT) assay.

207 FN) gamma and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40% of subjects, respectively

208 ptides in standard enzyme-linked immunospot (ELISPOT) assays predicts the recognition of cells infect

209 onses by IFN-gamma enzyme-linked immunospot (ELISPOT) assays to all 11 of these HCMV proteins, and ac

210 Using tetramer and enzyme-linked immunospot (ELISPOT) assays, we have observed cytomegalovirus (CMV)-

211 peptide epitope in enzyme-linked immunospot (ELISPOT) assays.

212 d gamma interferon enzyme-linked immunospot (ELISPOT) assays.

213 was analyzed using enzyme-linked immunospot (ELISPOT) by testing recipient peripheral blood mononucle

214 roduction using an enzyme-linked immunospot (ELISPOT) CMV assay (T-SPOT.CMV assay).

215 by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for cli

216 ity, measured with enzyme-linked immunospot (ELISPOT) interferon gamma release assay at 20 weeks gest

217 By contrast, enzyme-linked immunospot (ELISPOT), flow cytometry, time-of-flight mass cytometry

218 in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gamma secretion, and cytotoxi

219 included IFN-gamma enzyme-linked immunospot (ELISPOT), reverse transcription-polymerase chain reactio

220 e gamma interferon enzyme-linked immunospot (ELISPOT), tetramer, and intracellular cytokine staining

221 ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group.

222 ay (FLISA) and enzyme linked immunospotting (ELISPOT).

223 ng cells per 10(5) input cells (p < 0.01) in ELISPOT assays for IFN-gamma secretion.

224 , overlapping (OL) peptides were analyzed in ELISPOT assays and OL8 was able to activate both CD8(+)

225 No differences in ELISPOT responses comparing prednisone and placebo group

226 ) producing T-cell populations were found in ELISPOT.

227 months after transplantation was highest in ELISPOT-negative patients receiving kidneys from donors

228 ctive" CD8(+) T-cell responses identified in ELISPOT and ICS assays using a single high concentration

229 m donors younger than 50 years and lowest in ELISPOT-positive recipients with donors 50 years or olde

230 dian (HD) vintage was 46 mo (0 to 125 mo) in ELISPOT (+) patients versus 24 mo (0 to 276 mo) in ELISP

231 T (+) patients versus 24 mo (0 to 276 mo) in ELISPOT (-) patients (P = 0.009).

232 e median single peptide-specific response in ELISPOT was 43/10 peripheral blood mononuclear cells.

233 MCs from allergic individuals were tested in ELISPOT assays with overlapping peptides spanning known

234 Reactivity of T cells was tested in ELISPOT IFN-gamma assays against DC pulsed individually

235 This gamma interferon ELISPOT assay provides a new tool to apply in clinical s

236 ls tested ex vivo using the gamma interferon ELISPOT assay.

237 enicity was associated with gamma interferon ELISPOT responses to Gag and Env that were generated ear

238 Gamma interferon ELISPOT responses were similar for CCA and reassortant s

239 iated immunity (VZV-CMI) by gamma-interferon ELISPOT and responder cell frequency assays and for VZV

240 ll response was assessed by gamma-interferon ELISPOT in 42 BMT recipients (21 with cGVHD) and 30 heal

241 The cellular immunoblot, U.K.-ELISPOT, and T-cell proliferation assays can distinguish

242 Responses in the cellular immunoblot, U.K.-ELISPOT, and T-cell proliferation assays could different

243 om all peptide pools were combined, the mean ELISPOT signal per 10,000 cells at the time of BKVN diag

244 ls of IL-2, IL-4, IL-10, and IFN-gamma mRNA; ELISPOT assay showed an equivalent number of IL-4- and I

245 Posttransplant conversion to a negative ELISPOT assay occurred in 86% of patients who received i

246 sment of CMV-specific immunity using a novel ELISPOT assay is able to predict protection from CMV inf

247 Measurement of CMV-CMI using a novel ELISPOT assay would be useful clinically to monitor allo

248 ween these possibilities, we devised a novel ELISPOT, using cultured donor, recipient and third-party

249 in 38% of ELISPOT (+) patients versus 14% of ELISPOT (-) patients (P = 0.008).

250 Acute rejection occurred in 38% of ELISPOT (+) patients versus 14% of ELISPOT (-) patients

251 esponses were studied using a combination of ELISPOT assays, tetramer staining, and FACS analysis to

252 The prevalence and magnitude of ELISPOT responses were greater in adult (5-15 years of a

253 ediated immunity [CMI], measured by means of ELISPOT analysis) in individuals aged >/= 70 years who r

254 us-infected persons was determined by use of ELISPOT.

255 fic immune responses, measured by gpELISA or ELISPOT, at approximately 28 days post-dose 4.

256 Positive ELISPOT assay results, but not positive results for CD4(

257 If confirmed prospectively, pretransplant ELISPOT assessments could be used to guide decision maki

258 s or older and a positive pretransplantation ELISPOT assay was more strongly associated with AR (odds

259 in patients with positive pretransplantation ELISPOT assays versus those with negative assays (36% vs

260 In this study, we report the quantitative ELISPOT method for simultaneous estimation of single-cel

261 The class II tetramer and U.S. ELISPOT assays performed less well.

262 eventing CMV reactivation was a CMV-specific ELISPOT response above the determined thresholds (adjust

263 nses could be tracked with cytokine-specific ELISPOT assays.

264 The SIV-specific ELISPOT response was predominantly mediated by CD8+ T ly

265 ells by enzyme-linked immune absorbent spot (ELISPOT) at month 3 and cidofovir use.

266 try and enzyme-linked immune absorbent spot (ELISPOT) in freshly prepared single-cell suspensions fro

267 to DBY by enzyme-linked immunosorbent spot (ELISPOT) and enzyme-linked immunosorbent assay.

268 interferon enzyme-linked immunosorbent spot (ELISPOT) assay responses to a panel of 257 optimally def

269 ition, the Enzyme-linked immunosorbent spot (ELISPOT) assay revealed suppression of interferon (IFN)-

270 tide-based enzyme-linked immunosorbent spot (ELISPOT) assay to determine whether assay results could

271 eron-gamma enzyme-linked immunosorbent spot (ELISPOT) assay to measure the cellular immune response t

272 IFN-gamma) enzyme-linked immunosorbent spot (ELISPOT) assay used to detect T-cell responses to a pane

273 An enzyme-linked immunosorbent spot (ELISPOT) assay was used to measure the frequency of peri

274 IFN) gamma enzyme-linked immunosorbent spot (ELISPOT) assays and increased expression of the maturati

275 stimulated enzyme-linked immunosorbent spot (ELISPOT) assays for interferon gamma were analyzed retro

276 eron-gamma enzyme-linked immunosorbent spot (ELISPOT) frequencies assessed pre and postkidney transpl

277 roduction (enzyme-linked immunosorbent spot [ELISPOT] assays) by splenocytes from IKEPLUS-immunized C

278 peptides tested were recognized in standard ELISPOT and intracellular cytokine stain (ICS) assays.

279 As with rhesus macaques, Th2 ELISPOT responses to SIV were absent or >10-fold lower t

280 The ELISPOT assay was positive in 31 (41%) and negative in 4

281 On multivariate analysis, the ELISPOT CMV responses and steroids use were the only pre

282 at the protective epitopes identified by the ELISPOT analysis correspond almost perfectly to such reg

283 tly in primary or secondary infection by the ELISPOT assay and in secondary infection by MHC/peptide

284 In the ELISPOT (-) cohort, acute rejection rates ( approximatel

285 S-CoV-2 spike or nucleocapsid protein in the ELISPOT assay.

286 These studies were substantiated using the ELISPOT assay and a bulk cytokine release assay.

287 nd 58% sc-TCMR showed HR-kSORT), whereas the ELISPOT showed high precision ruling out sc-TCMR (specif

288 tor status and INH treatment with respect to ELISPOT results over time.

289 ld-type NPM1 and NPM1(mut) were subjected to ELISPOT analysis in 33 healthy volunteers and 27 AML pat

290 ransplant recipients at 43 centers underwent ELISPOT testing to enumerate interferon gamma (IFN-gamma

291 We used ELISPOT and staining assays for intracellular cytokines

292 RESEARCH DESIGN AND We used ELISPOT to characterize the frequency and functional phe

293 amma and interleukin 4 cell expression using ELISPOT technique.

294 +) expression on B cells were measured using ELISPOT and flow cytometry, respectively.

295 in-specific effector T cells was shown using ELISPOT assays and adoptive T cell transfer experiments.

296 cytometry, and xenoreactive lymphocytes via ELISPOT, 90 days after implantation.

297 infected individuals were tested in ex vivo ELISPOT assays with overlapping peptides spanning the en

298 We have analyzed by ex vivo ELISPOT the anti-vaccinia cytotoxic T lymphocyte respons

299 ainst mismatched antigens were measured with ELISPOT and ELISA, and the effect of GVH recognition ass

300 we counted the number of peptide pools with ELISPOT activity of greater than 10 spots per well after